Abstracts tagged "outcome measures and rheumatoid arthritis (RA)"

Abstract Number: 1311 • 2012 ACR/ARHP Annual Meeting
A Novel Individualized Treatment Approach in Open-Label Extension Study of Ozoralizumab (ATN-103) in Subjects with Rheumatoid Arthritis On a Background of Methotrexate
Roy Fleischmann¹, Steven De Bruyn², Christian Duby², Katrien Verschueren³, Judith Baumeister⁴, Laura Sargentini-Maier⁵, Cedric Ververken⁶ and Josefin-Beate Holz⁷, ¹Southwestern Medical Center at Dallas, University of Texas, Dallas, TX, ²Clinical Development, Ablynx N.V., Zwijnaarde, Belgium, ³Clinical Development, Ablynx nv, Zwijnaarde, Belgium, ⁴Department of Pharmacology, Ablynx N.V., Zwijnaarde, Belgium, ⁵Pharmacology, Ablynx N.V., Zwijnaarde, Belgium, ⁶Project Management, Ablynx N.V., Zwijnaarde, Belgium, ⁷Chief Medical Officer, Ablynx N.V., Zwijnaarde, Belgium
Background/Purpose: Ozoralizumab (ATN-103), a novel TNFα inhibitor, is a trivalent, bispecific Nanobody® that potently neutralises TNF and binds to human serum albumin to increase its…
Abstract Number: 1045 • 2012 ACR/ARHP Annual Meeting
Dynamic Contrast-Enhanced Magnetic Resonance Imaging of the Wrist in Rheumatoid Arthritis Patients Treated with Methotrexate, Intra-Articular Glucocorticoid and Adalimumab/Placebo
Mette Bjørndal Axelsen¹, Merete L. Hetland², Kim Hørslev-Petersen³, Kristian Stengaard-Pedersen⁴, Peter Junker⁵, Jan Pødenphant⁶, Jakob M. Møller⁷, Henning Bliddal⁸, Olga Kubassova⁹, Mikael Boesen¹⁰ and Mikkel Østergaard¹¹, ¹Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Copenhagen University Hospital at Glostrup, Copenhagen, Denmark, ²Copenhagen University Hospital Glostrup, Copenhagen, Denmark, ³Institute of Regional Health Services Research, University of Southern Denmark, Graasten, Denmark, ⁴Arhus University Hospital, Aarhus, Denmark, ⁵Odense University Hospital, Odense, Denmark, ⁶Copenhagen University at Gentofte, Hellerup, Denmark, ⁷Department of Radiology, Copenhagen University Hospital in Herlev, Copenhagen, Denmark, ⁸Department of Rheumatology, The Parker Institute, Copenhagen University Hospital at Frederiksberg, Copenhagen, Denmark, ⁹Image Analysis Ltd., Leeds, United Kingdom, ¹⁰The Parker Institute, Department of Rheumatology, Copenhagen University Hospital at Frederiksberg, Copenhagen, Denmark, ¹¹Dept of Rheumatology RM, Copenhagen University Hospital at Glostrup, Copenhagen, Denmark
Background/Purpose: To validate parameters of dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) in an early rheumatoid arthritis (RA) clinical trial by comparison with clinical parameters of…
Abstract Number: 769 • 2012 ACR/ARHP Annual Meeting
2010 ACR/EULAR Rheumatoid Arthritis Classification Criteria Predicts Radiogical, but Not Clinical Outcomes At 18 Months Into Disease in a Canadian Early Arthritis Cohort
Ariel Masetto¹, Arthur J. Fernandes², Patrick Liang³, Pierre Cossette⁴ and Gilles Boire⁵, ¹Rheumatology, CHUS, Fleurimont, QC, Canada, ²Rheumatology Division, Universite de Sherbrooke, Sherbrooke N, Canada, ³Rheumatology Division, CHUS, Sherbrooke, QC, Canada, ⁴Internal Medicine Departement, Centre Hospitalier Universitaire de Sherbrooke, Université de Sherbrooke, Sherbrooke, QC, Canada, ⁵Rheumatology Division, Centre Hospitalier Universitaire de Sherbrooke, Université de Sherbrooke, Sherbrooke, QC, Canada
Background/Purpose: The potential of the 2010 ACR/EULAR rheumatoid arthritis (RA) classification criteria to discriminate early arthritis patients according to their clinical and radiological outcomes needs…
Abstract Number: 495 • 2012 ACR/ARHP Annual Meeting
Comparison of Discontinuation Rates by Biologic Since 1998 in US Patients with Rheumatoid Arthritis
Sofia Ramiro¹, Frederick Wolfe², David J. Harrison³, George Joseph³, David H. Collier³, Désirée van der Heijde⁴, Robert Landewé⁵ and Kaleb Michaud⁶, ¹Clinical Immunology & Rheumatology, Academic Medical Center, University of Amsterdam, The Netherlands and Hospital Garcia de Orta, Almada, Portugal, ²National Data Bank for Rheumatic Diseases, Wichita, KS, ³Amgen Inc., Thousand Oaks, CA, ⁴Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ⁵Clinical Immunology & Rheumatology, Academic Medical Center, University of Amsterdam and Atrium Medical Center, Heerlen, Netherlands, ⁶Rheumatology, National Data Bank for Rheumatic Diseases & University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Since discontinuation may be a surrogate for ineffectiveness, we measured rates and reasons for biologic discontinuation in a real-world setting. Methods: From 1998 to…
Abstract Number: 421 • 2012 ACR/ARHP Annual Meeting
Rheumatoid Factor, Not Antibodies to Citrullinated Proteins, Are Associated with High Disease Activity
Josef S. Smolen¹, Farideh Alasti² and Daniel Aletaha³, ¹Medical University of Vienna and Hietzing Hospital, Vienna, Austria, ²Department of Medicine III, Division of Rheumatology, Medical University of Vienna, Vienna, Austria, ³Department of Internal Medicine III, Division of Rheumatology, Medical University of Vienna, Vienna, Austria
Background/Purpose: Autoantibodies in general, and rheumatoid factor (RF) and anti-citrullinated peptide antibodies (ACPA) in particular, are a hallmark of RA. After their characterization, ACPA have…
Abstract Number: 391 • 2012 ACR/ARHP Annual Meeting
DAS28 Is Not a Sufficient Disease Activity Measure for Obese Rheumatoid Arthritis Patients – Don’t Leave the Feet Behind
Vikram Garg¹, Paul Maranian², Mihaela B. Taylor³, Harold E. Paulus⁴, David Elashoff⁵ and Veena K. Ranganath⁶, ¹Division of Rheumatology, UCLA David Geffen School of Medicine, VA Greater Los Angeles Healthcare System, Los Angeles, CA, ²Division of Rheumatology, UCLA Medical School, Los Angeles, CA, ³Rheumatology, University of California Los Angeles, Los Angeles, CA, ⁴Medicine-Rheumatology, UCLA David Geffen School of Medicine, Los Angeles, CA, ⁵Departments of Biostatistics and Medicine, University of California, Los Angeles, Los Angeles, CA, ⁶Medicine/Rheumatology, University of California, Los Angeles, Western Consortium of Practicing Rheumatologists, Los Angeles, CA
Background/Purpose: Current literature suggests that obesity impacts disease activity in rheumatoid arthritis (RA) and the incidence of obesity is on the rise. The objective of…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.